ALGN vs. BSX: Align vs. Boston Scientific Stock Comparison

Company Profile

Align (ALGN) and Boston Scientific (BSX) both belong to the Health Care Equipment & Supplies industry, though ALGN is classified under Health Care Supplies while BSX falls under Health Care Equipment.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Align (ALGN) has an aggressive beta of 1.67, indicating higher sensitivity to broad-market moves, while Boston Scientific (BSX) is defensive at 0.57 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Boston Scientific (BSX) is heavily traded at around 19.73M shares per day, whereas Align (ALGN) sees a more moderate 942.14K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Align (ALGN) at 11.91% and Boston Scientific (BSX) at 14.12% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

For every dollar of sales, both Align (ALGN) at 11.83% and Boston Scientific (BSX) at 16.62% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Align (ALGN) at 20.13% and Boston Scientific (BSX) at 19.05% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Boston Scientific (BSX) at 19.87% is around its peer norm for revenue growth, while Align (ALGN) at 0.90% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Boston Scientific (BSX) at 55.20% sits in the top EPS growth quartile, while Align (ALGN) at 0.53% is closer to the peer norm — faster per-share earnings growth for BSX.

Growth Metrics

Financial Strength

Align (ALGN) at 1.43 keeps current ratio within its industry’s typical mid-range, while Boston Scientific (BSX) at 1.37 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BSX.

Align (ALGN) at 0.03 keeps leverage in the lower industry quartile, while Boston Scientific (BSX) at 0.46 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Align (ALGN) nor Boston Scientific (BSX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Align (ALGN) nor Boston Scientific (BSX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Boston Scientific (BSX) at 18.04 sits in the cheaper P/E ratio quartile, while Align (ALGN) at 24.20 is closer to its industry’s usual earnings multiple — a discount for BSX, though growth and earnings durability still matter.

On P/S ratio, both Align (ALGN) at 2.81 and Boston Scientific (BSX) at 2.94 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Align (ALGN) at 2.73 and Boston Scientific (BSX) at 2.42 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics